Alzamend Neuro Regains Nasdaq Compliance Over Listing Requirements

MT Newswires Live10-15

Alzamend Neuro (ALZN) said Tuesday it is now in compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement for continued listing.

Earlier this year, the company agreed to sell $25 million of its series A convertible preferred stock to an investor over a period of time. Alzamend said the investor has so far bought $8 million of the shares, with an additional $2 million to be funded within the next 30 days.

The investor is obligated to buy $1 million of the shares every month until January 2026, the company said.

The company's shares were down 4.2% in recent trading.

Price: 1.61, Change: -0.07, Percent Change: -4.17

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475902687?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-15 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475902687","market":"sh","top_or_hot":-1,"title":"Alzamend Neuro Regains Nasdaq Compliance Over Listing Requirements","media":"MT Newswires Live","content":"<html><body><p> Alzamend Neuro (ALZN) said Tuesday it is now in compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement for continued listing.</p><p>Earlier this year, the company agreed to sell $25 million of its series A convertible preferred stock to an investor over a period of time. Alzamend said the investor has so far bought $8 million of the shares, with an additional $2 million to be funded within the next 30 days.</p><p>The investor is obligated to buy $1 million of the shares every month until January 2026, the company said.</p><p>The company's shares were down 4.2% in recent trading.</p><p>Price: 1.61, Change: -0.07, Percent Change: -4.17</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alzamend Neuro Regains Nasdaq Compliance Over Listing Requirements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlzamend Neuro Regains Nasdaq Compliance Over Listing Requirements\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-15 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alzamend Neuro (ALZN) said Tuesday it is now in compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement for continued listing.Earlier this year, the company agreed to sell $25 ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SQQQ","symbol_name":"纳指三倍做空ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2475902687","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475902687","pubTimestamp":1729003444,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alzamend Neuro  said Tuesday it is now in compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement for continued listing.Earlier this year, the company agreed to sell $25 million of its series A convertible preferred stock to an investor over a period of time. Alzamend said the investor has so far bought $8 million of the shares, with an additional $2 million to be funded within the next 30 days.The investor is obligated to buy $1 million of the shares every month until January 2026, the company said.The company's shares were down 4.2% in recent trading.Price: 1.61, Change: -0.07, Percent Change: -4.17","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF","ALZN":"Alzamend Neuro, Inc","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","PSQ":"纳指反向ETF","BK4539":"次新股","TQQQ":"纳指三倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","QID":"纳指两倍做空ETF","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC",".IXIC":"NASDAQ Composite"},"translate_title":"Alzamend Neuro重新遵守纳斯达克上市要求","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALZN":1,".IXIC":1,"NDAQ":1,"NQmain":1,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"MNQmain":0.6},"content_text":"Alzamend Neuro (ALZN) said Tuesday it is now in compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement for continued listing.Earlier this year, the company agreed to sell $25 million of its series A convertible preferred stock to an investor over a period of time. Alzamend said the investor has so far bought $8 million of the shares, with an additional $2 million to be funded within the next 30 days.The investor is obligated to buy $1 million of the shares every month until January 2026, the company said.The company's shares were down 4.2% in recent trading.Price: 1.61, Change: -0.07, Percent Change: -4.17","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475902687"}